BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...2/27/19 $75.0 $444.5 $345.8 -22% CStone Pharmaceuticals Co. Ltd. (HKEX:2616) 2/25/19 $327.7 $1,547.3 $1,493.1 -3% Cellid Co. Ltd....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...TPEx-E:6589) 12/18/18 TBD Ph III (biosimilar) Shanghai Henlius Biotech Inc. (HKEX) 12/14/18 TBD Reg (biosimilar) Cellid Co. Ltd....
BioCentury | Jan 4, 2019
Financial News

Cellid proposes Korean IPO

...Cell-based vaccine company Cellid Co. Ltd. (Seoul, South Korea) proposed on Dec. 13 to sell 1.2 million shares...
...in a Korean IPO, according to the Korean Stock Exchange's website. At the W24,550 mid-point, Cellid...
...16 or 18-positive cervical cancer. Samsung Securities is underwriting the IPO. Cellid Co. Ltd., Seoul, South Korea Chris Lieu BVAC-C Cellid Co. Ltd. E6...
Items per page:
1 - 3 of 3
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...2/27/19 $75.0 $444.5 $345.8 -22% CStone Pharmaceuticals Co. Ltd. (HKEX:2616) 2/25/19 $327.7 $1,547.3 $1,493.1 -3% Cellid Co. Ltd....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...TPEx-E:6589) 12/18/18 TBD Ph III (biosimilar) Shanghai Henlius Biotech Inc. (HKEX) 12/14/18 TBD Reg (biosimilar) Cellid Co. Ltd....
BioCentury | Jan 4, 2019
Financial News

Cellid proposes Korean IPO

...Cell-based vaccine company Cellid Co. Ltd. (Seoul, South Korea) proposed on Dec. 13 to sell 1.2 million shares...
...in a Korean IPO, according to the Korean Stock Exchange's website. At the W24,550 mid-point, Cellid...
...16 or 18-positive cervical cancer. Samsung Securities is underwriting the IPO. Cellid Co. Ltd., Seoul, South Korea Chris Lieu BVAC-C Cellid Co. Ltd. E6...
Items per page:
1 - 3 of 3